शुभ दीपावलीDiwali offer: 3 months free on yearly plans · ends 11 NovSee plans
IPCALABNSEIPCA LABORATORIES LTD· Pharmaceuticals & BiotechnologyHighNeutral
Announced Thu, 5 Nov, 2026 · 13:42 IST

Q2 FY27: consolidated revenue up 14%, profit after tax up 33%, EBITDA margin expands

Profit growth above 25%EBITDA margin expansionExceptional itemResults View source PDFExplain this filing

IPCALAB · price

Loading chart…

▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.

Price reactionminutes from the announcement price · days from the prior close
-1.1%Reaction day
₹1972.90
prior close
₹1959.40
announcement price
In-mkt
timing
Nifty Midcap 150marketpendingvs market: pending
Pharmaceuticals peers, median of 171sector+0.5%-1.6% vs sector

On the reaction day the stock moved 1.6 pts less than its Pharmaceuticals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.

Minutes after the announcementfrom the announcement price · no benchmark
Stock
5m
-0.5
10m
-0.9
15m
-0.9
30m
-1.6
Sessions after the filingfrom the prior close
StockMarketvs marketSectorvs sector
Reaction day
-1.1pendingpending+0.5-1.6
Next day
-1.8pendingpending+0.4-2.2
2d
—————
3d
—————
4d
—————
5d
—————
1w
—————
15d
—————
1m
—————
2m
—————
3m
—————
UpDownMarket · Nifty Midcap 150Sector · Pharmaceuticals peers, median of 171Pending

Minute windows have no benchmark: there is no intraday index history to compare against.

AI summary

Consolidated Q2 ended September 30, 2026: revenue from operations rose 14% to Rs 2,909.94 crore from Rs 2,556.50 crore, and profit after tax attributable to owners rose 33% to Rs 375.13 crore from Rs 282.57 crore. EBITDA margin rose to 22.97% from 21.68%; a Rs 24.26 crore claim was booked as an exceptional item. Consolidated H1: revenue Rs 5,698.04 crore, up 17%; profit after tax Rs 777.02 crore, up 51%. The auditor review was unmodified.

Likely market impact

Positive: revenue and profit grew in Q2 and EBITDA margin expanded, supporting earnings sentiment despite the Rs 24.26 crore claim provision.

By the numbers

The filed figures for this quarter have not reached us in XBRL yet, so there is nothing to compute here; the read above is the AI's, from the document. The table appears the moment the figures land.